Central giant cell granuloma of the jawbones - new insights into molecular biology with clinical implications on treatment approaches

Histology and Histopathology

Volumn 23, Issue 9, 2008, Pages 1151-1160

  Vered, Marilena ^a   Buchner, Amos ^a   Dayan, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Central giant cell granuloma; Molecular markers; Pharmacological agents

Indexed keywords

ANTINEOPLASTIC AGENT;

CELL TRANSFORMATION; DRUG DESIGN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GIANT CELL GRANULOMA; HUMAN; JAW DISEASE; MOLECULAR BIOLOGY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOMA, GIANT CELL; HUMANS; MANDIBULAR DISEASES; MOLECULAR BIOLOGY;

EID: 84863989947     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Abbas S., Clohisy J.C. and Abu-Amer Y. (2003). Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J. Orthop. Res. 21, 1041-1048.
2. Abukawa H., Kaban L.B., Williams W.B., Terada S., Vacanti J.P. and Troulis M.J. (2006). Effect of interferon alpha-2b on porcine mesenchymal stem cells. J. Maxillofac. Surg. 64, 1214-1220.
3. Bocci G., Fasciani A., Danesi R., Viacava P., Genazzani A.R. and Del Tacca M. (2001). In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. Mol. Hum. Reprod. 7, 771-777.
4. Boyle W.J., Simonet W.S. and Lacey D.L. (2003). Osteoclast differentiation and activation. Nature 423, 337-342.
5. Carlos R. and Sedano H.O. (2002). Intralesional corticosteroids as an alternative treatment for central giant cell granuloma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 93, 161-166.
6. Choi B.K., Moon S.Y., Cha J.H., Kim K.W. and Yoo Y.J. (2005). Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Pophyromonas gingivalis, Treponema denticola, and Treponema socranskii. J. Periodontol. 76, 813-820.
7. Chuong R., Kaban L.B., Kozakewich H. and Perez-Atayade A. (1986). Central giant cell lesions of the jaws: a clinicopathologic study. J. Oral Maxillofac. Surg. 44, 798-813.
8. Collin-Osbody P., Rothe L., Bekker S., Anderson F., Huang Y. and Osbody P. (2002). Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J. Bone Miner. Res. 17, 1859-1871.
9. Collins A. (2000). Experience with anti-angiogenic therapy of giant cell granuloma of the facial bones. Ann. R. Australas. Coll. Dent. Surg. 15, 170-175.
10. Comert E., Turanli M. and Ulu S. (2006). Oral and intralesional steroid therapy in giant cell granuloma. Acta Otolaryngol. 126, 664-666.
11. de Lange J., Rosenberg A.J., van der Akker H.P., Koole R., Wirds J.J. and van der Berg van der Berg H. (1999). Treatment of a central giant cell granuloma of the jaw with calcitonin. Int. J. Oral Maxillofac. Surg. 28, 372-376.
12. de Lange J., van den Akker H.P., Veldhuijzen van Zanten G.O., Engelshove H.A., van der Berg H. and Klip H. (2006a). Calcitonin therapy in central giant cell granuloma of the jaw: a randomized double-blind placebo-controlled study. Int. J. Oral Maxillofac. Surg. 35, 791-795.
13. de Lange J., van den Akker H.P., van den Berg H., Richel D.J. and Gortzak R.A. (2006b). Limited regression of central giant cell granuloma by interferon alpha after failed calcitonin therapy: a report of 2 cases. Int. J. Oral Maxillofac. Surg. 35, 865-869.
14. El-Labban N.G. (1997). Intravascular fibrin thrombi and endothelial cell damage in central giant cell granuloma. J. Oral Pathol. Med. 26, 1-5.
15. Ferrara N. (2002). VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803.
16. Ferrara N., Gerber H-P. and LeCouter J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
17. Flanagan A.M., Nui B., Tinkler S.M., Horton M.A., Williams D.M. and Chambers T.J. (1988). The multinucleate cells in giant cell granuloma of the jaws are osteoclasts. Cancer 62, 1139-1145.
18. Folkman J. (2002). Antiangiogenetic therapy with interferon alpha for giant cell lesions of the jaws (comment). J. Oral Maxillofac. Surg. 60, 1111-1113.
19. Fukashima H., Jimi E., Okamato F., Motokawa W. and Okabe K. (2005). IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. Bone 36, 267-275.
20. Gamberi G., Benassi M.S., Bohling T., Ragazzini P., Molendini L., Sollazzo M.R., Merli M., Ferrari C., Magagnoli C., Bertoni F. and Picci P. (1998). Prognostic relevance of c-myc gene expression in giant cell tumor of bone. J. Orthop. Res. 16, 1-7.
21. Goldman K.E. (2005). Complications of alpha-interferon therapy for aggressive central giant cell lesion of the maxilla. Oral Surg. Oral Med. Oral Pathol. Oral Endod. Radiol. 100, 285-291.
22. Han S.Y., Lee N.K., Kim K.H., Jang I.W., Yim M., Kim J.H., Lee W.J. and Lee S.Y. (2005). Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood 106, 1240-1245.
23. Harris M. (1993). Central giant cell granulomas of the jaws regress with calcitonin therapy. Br. J. Oral Maxillofac. Surg. 31, 89-94.
24. Heiss J.D., Papavassiliou E., Merrill M.J., Nieman L., Knightly J.J., Walbridge S., Edwards N.A. and Oldfield E.H. (1996). Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability. J. Clin. Invest. 98, 1400-1408.
25. Herlaar E. and Brown Z. (1999). P38 MAPK signaling cascades in inflammatory disease. Mol. Med. Today 5, 439-447.
26. Ip Y.T. and Davis R.J. (1998). Signal transduction by the c-jun N-terminal kinase - from inflammation to development. Curr. Opin. Cell Biol. 10, 205-219.
27. Jaffe H.L. (1953). Giant cell reparative granuloma, traumatic bone cyst and fibrous (fibro-osseous) dysplasia of the jawbones. Oral Surg. Oral Med. Oral Pathol. 6, 159-175.
28. Kaban L.B., Mulliken J.B., Ezekowitz R.A., Ebb D., Smith P.S. and Folkman J. (1999). Antiangiogenetic therapy of a recurrent giant cell tumor of the mandible with interferon alpha-2a. Pediatrics. 103 (6 Pt 1), 1145-1149.
29. Kaban L.B., Troulis M.J., Ebb M., August M., Hornicek F.J. and Dodson T.B. (2002). Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J. Oral Maxillofac. Surg. 60, 1103-1111.
30. Kaban L.B., Troulis M.J., Wilkinson M.J., Ebb D. and Dodson T.B. (2007). Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J. Oral Maxillofac. Surg. 65, 2018-2023. (Discussion p. 2024).
31. Kaden J.J., Kilic R., Sarikoc A., Hagl S., Lang S., Hoffman U., Bruekmann M. and Borggrefe M. (2005). Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int. J. Mol. Med. 16, 869-872.
32. Kaffe I., Ardekian L., Taicher S., Littner M.M. and Buchner A. (1996). Radiologic features of central giant cell granuloma of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 81, 720-726.
33. Kumta S.M., Huang L., Cheng Y.Y., Chow L.T.C., Lee K.M. and Zheng M.H. (2003). Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci. 73, 1427-1436.
34. Lau Y.S., Sabokbar A., Gibbons C.L., Giele H. and Athanasou N. (2005). Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum. Pathol. 36, 945-954.
35. Leung D.W., Cachianes G., Kuang W-J., Goeddel D.V. and Ferrara N. (1989). Vascular endothelial factor is a secreted angiogenic mitogen. Science 246, 1306-1312.
36. Li B., Yu S-F. and Li T-J. (2003). Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. J. Oral Pathol. Med. 32, 367-375.
37. Lim L. and Gibbins J.R. (1995). Immunohistochemical and ultrastructural evidence of a modified microvasculature in the giant cell granuloma of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 79, 190-198.
38. Manabe N., Oda H., Nakamura K., Kuga Y., Uchida S. and Kawaguchi H. (1999). Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology 38, 714-720.
39. Matsumoto M., Sudo T., Saito E., Osada H. and Tsujimoto M. (2000). Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 275, 31155-31161.
40. Montero A., Okada Y., Tomita M., Ito M., Tsurakami H., Nakamura T., Doetscman T., Coffin J.D. and Hurley M.M. (2000). Disruption of the fibroblast growth factor 2-gene results in decreased bone mass and bone formation. J. Clin. Invest. 105, 1085-1093.
41. Niida S., Kaku M., Amano H., Yoshida H., Kataola H., Nishikawa S., Tanne K., Maeda N., Nishikawa S. and Kodama H. (1999). Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190, 293-298.
42. Okada Y., Montero A., Zhang X., Sobue T., Lorenzo J., Doetschman T., Coffin J. and Hurley M.M. (2003). Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. J. Biol. Chem. 23, 21258-21266.
43. Pakala R., Watanabe T. and Benedict CR. (2002). Induction of endothelial proliferation by angiogenic factors released by activated monocytes. Cardiovasc. Radiat. Med. 3, 95-101.
44. Parffit A.M. (1998). Osteoclast precursors as leukocytes: importance of the area code. Bone 23, 491-494.
45. Pinto L.P., Cherubinim K., Salum F.G., Yurgel L.S. and de Fugueiredo M.A. (2006). Highly aggressive brown tumor in the jaw associated with tertiary hyperparathyroidism. Pediatr. Dent. 28, 543-546.
46. Pogrel M.A. (2003). Calcitonin therapy for central giant cell granuloma. J. Oral Maxillofac. Surg. 61, 649-653.
47. Pogrel M.A., Regezi J.A., Harris S.T. and Goldring S.R. (1999). Calcitonin treatment for central giant cell granulomas of the mandible: report of two cases. J. Oral Maxillofac. Surg. 57, 848-853.
48. Pondel M. (2000). Calcitonin and calcitonin receptors: bone and beyond. Int. J. Exp. Pathol. 81, 405-422.
49. Rajamannan N.M., Nealis T.B., Subramanian M., Pandya S., Stock S.R., Ignatiev C.I., Bebo T.J., Rosengart T.K., Edwards W.D., McCarthy P.M., Bonow R.O. and Spelberg T.C. (2005). Calcified rheumatic neoangionesis is associated with vascular endothelial growth factor expression and osteoclast-like bone formation. Circulation. 111, 3269-3301.
50. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., Shapiro R.L., Galloway A.C., Rifkin D.B. and Mignatti P. (1998). Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol.141, 1659-1673.
51. Terry B.C. and Jacoway J.R. (1994). Management of central giant cell lesions: an alternative to surgical therapy. Oral Maxillofac. Surg. North. Am. 6, 579-600.
52. Tiffee J.C. and Aufdemorte T.B. (1997). Markers for macrophage and osteoclast lineages in giant cell lesions of the oral cavity. J. Oral Maxillofac. Surg. 55, 1108-1112.
53. Tobon-Arroyave S.I., Franco-Gonzales L.M., Isaza-Guzman D.M., Florez-Moreno G.A., Bravo-Vasquez T., Castaneda-Palez D.A. and Vieco-Duran B. (2005). Immunohistochemical expression of RANK, GRa and CTR in central giant cell granuloma of the jaws. Oral Oncol. 41, 480-488.
54. Tolany E., Kuhnen C., Voss B., Wiethege T. and Muller K-M. (1998). Expression and localization of vascular endothelial factor and its receptor flt in pulmonary sarcoidosis. Virchows Arch. 432, 61-65.
55. Vered M., Buchner A. and Dayan D. (2004). Immunohistochemical profile of glucocorticoid receptor, calcitonin receptor, CD68 and HLA-DR in central giant cell granuloma of the jawbone. J. Appl. Res. Clin. Dent. 1, 47-55.
56. Vered M., Shohat I., Buchner A., and Dayan D. (2005). Myofibroblasts in stroma of odontogenic cysts and tumors can contribute to variations in the biologic behavior of the lesions. Oral Oncol. 41, 1028-1033.
57. Vered M., Buchner A. and Dayan D. (2006a). Immunohistochemical expression of glucocorticoid and calcitonin receptors as a tool for selecting therapeutic approach in central giant cell granuloma of the jawbones. Int. J. Oral Maxillofac. Surg. 35, 756-760.
58. Vered M., Buchner A. and Dayan D. (2006b). Giant cell granuloma of the jawbones - A proliferative vascular lesion? Immuno-histochemical study with vascular endothelial growth factor and basic fibroblastic growth factor. J. Oral Pathol. Med. 35, 613-619.
59. Vered M., Nasrallah W., Buchner A. and Dayan D. (2007a). Stromal myofibroblasts in central giant cell granuloma of the jaws cannot distinguish between non-aggressive and aggressive lesions. J. Oral Pathol. Med. 36, 495-500.
60. Vered M., Shohat I., Buchner A., Dayan D. and Taicher S. (2007b). Calcitonin nasal spray for treatment of central giant cell granuloma - clinical, radiologic and histologic findings and immunohistochemical expression of calcitonin and glucocorticoid receptors. Oral Surg. Oral Med. Oral Pathol. Oral Endod. Radiol. 104, 226-239.
61. Waldron C.A. (1995). Bone pathology. In: Oral and maxillofacial pathology. Neville B.W., Damm D.D., Allen C.A. and Bouquot J.E. (eds). Saunders. Philadelphia, PA. pp 453-455.
62. Whitaker S.B. and Waldron C.A. (1993). Central giant cell lesions of the jaws. A clinical, radiologic, and histopathologic study. Oral Surg. Oral Med. Oral Pathol. 75, 199-208.
63. Yamashita A., Yonemitsu Y., Okano S., Nakagawa K., Nakashima Y., Irisa T., Iwamoto Y., Nagai Y., Hasegawa M. and Sueishi K. (2002). Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J. Immunol. 168, 450-457.
64. Zheng M.H., Xu J., Robbins P., Pavlos N., Wysocki S., Kumta S.M., Wood D.J. and Papadimitriou J.M. (2000). Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum. Pathol. 31, 804-812.
65. Zhou M., Sutliff R.L., Paul R.J., Lorenz J.N., Hoying J.B., Haundenschild C.C., Moying Y., Coffin J.D., Kong L., Kranias E.G., Luo W., Boivin G.P., Duffy J.J., Pawlowski S.A. and Doetschman T. (1998). Fibroblast growth factor 2 control of vascular tone. Nat. Med. 4, 207-210.